[Lacosamide in treatment of patients with focal epilepsy and comorbid mental disorders].

[Lacosamide in treatment of patients with focal epilepsy and comorbid mental disorders].

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(10. Vyp. 2):98-104

Authors: Yakovleva YA, Yanaeva AN, Spikina AA, Rukavitsyna EL

Abstract
In this article, the results of personal prospective observation of lacosamide (LCM) administration in 91 adults with epilepsy and comorbid mental disorders are presented. LCM was administered as a part of polytherapy for 80 patients at a dose of up to 400 mg/day and of monotherapy for 11 patients at a dose of up to 600 mg/day for up to 12 months. Clinical-psychopathological and experimental-psychological monitoring of patients' condition over time was carried out using the Mental Health Comprehensive Assessment Scale (MHCAS), the Global Clinical Impression scale (GCI). As a result, the majority of patients (58 people (63.7%)) achieved remission with good tolerability and positive changes in cognitive functions and emotional-volitional characteristics, confirming their stability after 1 year of LCM administration.

PMID: 30698552 [PubMed - in process]

from A via a.sfakia on Inoreader http://bit.ly/2GcYabV